Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC ...Middle East

A new study showed improved progression-free survival when systemic therapy is added to TACE for HCC. Overall survival outcomes are pending. Medscape Medical News

Hence then, the article about durvalumab plus bevacizumab improves tace outcomes in hcc was published today ( Tuesday 06/02/2024 - 01:33 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC )

Also on site :

• Potato futures are soaring – should the world be worried?
• Ukrainian arms firm linked to graft probe says NATO member froze factory project
• Starbucks to Cut 300 Jobs— Here's How to Handle a Layoff According to a Pro